Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib.
Sumaira KhalilTariq GhafoorAmna Kaneez Fatima RajaPublished in: Case reports in oncological medicine (2020)
Inflammatory myofibroblastic tumor (IMT) is a rare entity of neoplastic origin. It usually occurs in children and adolescents and most commonly involves pulmonary and gastrointestinal sites. Here, the authors present two cases; one is the nine months old boy with a subcutaneous IMT in the left temporal region that was treated successfully with surgical resection. To the best of our knowledge, this is the first reported case of a subcutaneous IMT in this particular region. The second is an eight years old girl with an IMT of the right hemi-pelvis. The mass had complete surgical excision with clear margins and no residual disease. She was kept on regular follow-up with ultrasound abdomen. However, her disease relapsed with the appearance of lesions in right iliac fossa, right ovary, and liver. Biopsy of the relapsed abdominal mass confirmed ALK-positive IMT. She was treated with ALK inhibitor Crizotinib. She was monitored with regular blood complete picture, hepatic and renal function test, and ultrasound abdomen. Her lesions started regressing within one month, and she achieved complete remission after 6 months of treatment.
Keyphrases
- advanced non small cell lung cancer
- acute lymphoblastic leukemia
- acute myeloid leukemia
- magnetic resonance imaging
- diffuse large b cell lymphoma
- healthcare
- oxidative stress
- multiple myeloma
- ultrasound guided
- computed tomography
- pulmonary hypertension
- systemic lupus erythematosus
- combination therapy
- contrast enhanced ultrasound